Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decipher a 300-page biopharma filing packed with clinical endpoints and FDA jargon can stall even seasoned analysts. Madrigal Pharmaceuticals鈥� SEC documents are no exception: every 10-K details Rezdiffra鈥檚 trial design, while 8-Ks flag pivotal data releases that can move the stock overnight. If you have searched for 鈥淢adrigal Pharmaceuticals SEC filings explained simply,鈥� you know the challenge.
Stock Titan cuts through that complexity. Our AI reads each Madrigal Pharmaceuticals quarterly earnings report 10-Q filing, highlights cash-runway updates, and links them to ongoing MAESTRO studies. Need fast context on a sudden press release? We deliver Madrigal Pharmaceuticals 8-K material events explained in plain English within minutes of EDGAR posting. AG真人官方-time alerts surface Madrigal Pharmaceuticals Form 4 insider transactions, so you can follow executive stock trades ahead of regulatory milestones. You will also find the annual report鈥�Madrigal Pharmaceuticals annual report 10-K simplified鈥攁nd an easy path to the Madrigal Pharmaceuticals proxy statement executive compensation that breaks down R&D-driven pay packages.
Whether you are monitoring Madrigal Pharmaceuticals insider trading Form 4 transactions, comparing Phase 3 expenses line-by-line, or seeking a concise Madrigal Pharmaceuticals earnings report filing analysis, our platform equips you to act decisively. AI-powered summaries, expert tagging, and comprehensive coverage of every form鈥�10-K, 10-Q, 8-K, S-3, plus Madrigal Pharmaceuticals executive stock transactions Form 4 in real time鈥攎ean fewer hours lost and more insights gained. Start understanding Madrigal Pharmaceuticals SEC documents with AI instead of wrestling with them.
Madrigal Pharmaceuticals鈥� Q2-25 10-Q shows the company鈥檚 first full quarter of Rezdiffra commercialization driving a dramatic top-line inflection. Net product revenue reached $212.8 m for the quarter and $350.1 m YTD, versus $14.6 m in the prior-year periods. Cost of sales was only $13.6 m YTD, yielding a gross margin above 96%, but heavy commercial scale-up spending pushed operating expenses to $476.6 m (up 45% YoY). Consequently, the H1 operating loss narrowed to $126.5 m from $314.6 m, with a GAAP net loss of $115.5 m (-$5.22/sh).
Cash, cash equivalents and marketable securities totalled $802.0 m at 30 Jun 25, down modestly from $931.3 m at year-end after $136 m operating cash burn and $212 m net investment inflow. Inventory rose to $63.5 m as launch stock builds. Accounts receivable increased to $79.2 m, and gross-to-net reserves expanded to $52.3 m, reflecting payer rebates and copay assistance.
Liabilities were $319.4 m, including $118.4 m outstanding on the Hercules loan. Post-quarter, Madrigal replaced this facility with a new $350 m initial draw (up to $500 m total) Blue Owl secured term loan maturing 2030, subject to a $100 m minimum cash covenant.
22.29 m shares were outstanding on 1 Aug 25. Management emphasises ongoing U.S. launch execution, EU regulatory progress, and outcome trials needed for full Rezdiffra approval and label expansion.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
